Research Report

Methamphetamine Research Report
References

  1. The RAND Corporation. The economic cost of methamphetamine use in the United States, 2005. The RAND Corporation, 2009. Available at: https://www.rand.org/content/dam/rand/pubs/monographs/2009/RAND_MG829.pdf. Last accessed March 22, 2013.
  2. Substance Abuse Center for Behavioral Health Statistics and Quality. Results from the 2021 National Survey on Drug Use and Health: Detailed Tables, SAMHSA. Accessed January 2023.
  3. Johnston, L. D., Miech, R. A., O'Malley, P. M., Bachman, J. G., Schulenberg, J. E., & Patrick, M. E. (2018). Monitoring the Future national survey results on drug use, 1975-2017: Overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan, 116 pp. Available at: https://monitoringthefuture.org/wp-content/uploads/2022/08/mtf-overview2017.pdf. Last accessed July 3, 2018.
  4. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2016. Admissions to and Discharges from Publicly Funded Substance Use Treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018. Available at https://www.samhsa.gov/data/sites/default/files/2016_Treatment_Episode_Data_Set_Annual_Revised.pdf. Last Accessed February 25, 2019.
  5. National Institute on Drug Abuse. DrugFacts: Methamphetamine. Available at https://www.nida.nih.gov/publications/drugfacts/methamphetamine. Last Accessed July 6, 2018.
  6. National Institute on Drug Abuse. Methamphetamine abuse linked to impaired cognitive and motor skills despite recovery of dopamine transporters. NIDA Notes 17(1), 2002. Available at: https://archives.nida.nih.gov/news-events/nida-notes/2002/04/methamphetamine-abuse-linked-to-impaired-cognitive-and-motor-skills-despite-recovery-of-dopamine-transporters. Last accessed March 22, 2013.
  7. Volkow, N.D.; Chang, L.; Wang G-J.; Fowler, J.S.; Leonido-Yee, M.; Franceschi, D.; Sedler, M.J; Gatley, S.J.; Hitzemann, R.; Ding, Y-S.; Logan, J.; Wong, C.; and Miller, E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158(3):377– 382, 2001.
  8. Volkow, N.D.; Chang, L.; Wang, G-J.; Fowler, J.S.; Franceschi, D.; Sedler, M.; Gatley, S.J.; Miller, E.; Hitzemann, R.; Ding, Y-S.; and Logan, J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21(23):9414–9418, 2001.
  9. Thompson, P.M.; Hayashi, K.M.; Simon, S.L.; Geaga, J.A.; Hong, M.S.; Sui, Y.; Lee, J.Y.; Toga, A.W.; Ling, W.; and London, E.D. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24:6028–6036, 2004.
  10. Chang, L.; Alicata, D.; Ernst, T.; and Volkow, N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 102(Suppl 1):16–32, 2007.
  11. London, E.D.; Simon, S.L.; Berman, S.M.; Mandelkern, M.A.; Lichtman, A.M.; Bramen, J.; Shinn, A.K.; Miotto, K.; Learn, J.; Dong, Y.; Matochik, J.A.; Kurian, V.; Newton, T.; Woods, R.; Rawson, R.; and Ling, W. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61:73–84, 2004.
  12. Groman, S.M.; Morales A.M.; Lee, B.; London, E.D.; Jentsch, J.D. Methamphetamine-induced increases in putamen gray matter associate with inhibitory control. Psychopharmacology 229(3):527-538, 2013. Abstract.
  13. Sekine, Y.; Ouchi, Y.; Sugihara, G.; Takei, N.; Yoshikawa, E.; Nakamura, K.; Iwata, Y.; Tsuchiya, K.J.; Suda, S.; Suzuki, K.; Kawai, M.; Takebayashi, K.; Yamamoto, S.; Matsuzaki, H.; Ueki, T.; Mori, N.; Gold, M.S.; and Cadet, J.L. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28(22):5756–5761, 2008.
  14. Ibid. 
  15. Salo, R.; Buonocore, M.H.; Leamon, M.;Natsuaki, T.; Waters, C.;Moore, C.D.;Galloway, G.P.; and Nordahl, T.E. Extended findings of brain metabolite normalization in MA-dependent subjects across sustained abstinence: A proton MRS study. Drug and Alcohol Dependence 113(2-3):113-138, 2011.
  16. Wang G-J; Volkow, N.D.; Chang, L.; Miller, E.; Sedler, M.; Hitzemann, R.; Zhu, W.; Logan, J.; Ma, Y.; and Fowler, J.S. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry 161(2):242–248, 2004.
  17. Kuehn, B.M. Meth use linked to risk of Parkinson disease. JAMA 306:814, 2011.
  18. Wouldes, T.; LaGasse, L.; Sheridan, J.; and Lester, B. Maternal methamphetamine use during pregnancy and child outcome: What do we know? N Z Med J 117:U1180, 2004.
  19. Smith, L.M.; LaGasse, L.L.; Derauf, C.; Grant, P.; Shah, R.; Arria, A., Huestis, M.; Haning, W.; Strauss, A.; Della Grotta, S.; Liu, J.; and Lester, B.M. The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics 118(3):1149–1156, 2006.
  20. Smith, L.M.: LaGasse, L.L.; Derauf, C.; Grant, P.; Shah, R.; Arria, A.; Huestis, M.; Haning, W.; Strauss, A.; Della Grotta, S.; Fallone, M.; Liu, J.; and Lester, B.M. Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicol Teratol 30(1):20–28, 2008. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2358984/. Last accessed April 9, 2013.
  21. Kiblawi ZN, Smith LM, Diaz SD, et al. Prenatal Methamphetamine Exposure and Neonatal and Infant Neurobehavioral Outcome: Results from the IDEAL Study. Substance abuse: Official publication of the Association for Medical Education and Research in Substance Abuse. 2014;35(1):68-73. doi:10.1080/08897077.2013.814614.
  22. Wouldes TA, LaGasse LL, Huestis MA, DellaGrotta S, Dansereau LM, Lester BM. Prenatal methamphetamine exposure and neurodevelopmental outcomes in children from 1 to 3 years. Neurotoxicology and teratology. 2014;42:77-84. doi:10.1016/j.ntt.2014.02.004.
  23. Kiblawi, Z.N.; Smith, L.M.; LaGasse, L.L.; Derauf, C.; Newman, E.; Shah, R.; Arria, A.; Huestis, M.; DellaGrotta, S.; Dansereau, L.M.; Neal, C.; and Lester, B. The effect of prenatal methamphetamine exposure on attention as assessed by continuous performance tests: Results from the Infant Development, Environment, and Lifestyle study. J Dev Behav Pediatr 34(1):31–37, 2013.
  24. Himes SK, LaGasse LL, Derauf C, et al. Risk for Neurobehavioral Disinhibition in Prenatal Methamphetamine-Exposed Young Children with Positive Hair Toxicology Results. Therapeutic drug monitoring. 2014;36(4):535-543.
  25.  Smith LM, Diaz S, LaGasse LL, et al. Developmental and behavioral consequences of prenatal methamphetamine exposure: a review of the Infant Development, Environment, and Lifestyle (IDEAL) Study. Neurotoxicology and teratology. 2015;51:35-44. doi:10.1016/j.ntt.2015.07.006.
  26. Eze N, Smith LM, LaGasse LL, et al. School-Aged Outcomes following Prenatal Methamphetamine Exposure: 7.5 Year Follow-Up From The Infant Development, Environment, and Lifestyle (IDEAL) Study. The Journal of pediatrics. 2016;170:34-38.e1. doi:10.1016/j.jpeds.2015.11.070.
  27. Diaz S, Smith LM, LaGasse, LL, et al. Effects of Prenatal Methamphetamine Exposure on Behavioral and Cognitive Findings at 7.5 Years of Age. The Journal of Pediatrics. 2014;164:1333-38. doi: 10.1016/j.jpeds.2014.01.053.
  28. Ellis, R.J.; Childers, M.E.; Cherner, M.; Lazzaretto, D.; Letendre, S.; and the HIV Neurobehavioral Research Center Group. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 188(12):1820–1826, 2003.
  29. Fairbairn, N.; Kerr, T.; Milloy, M.-J.; Zhang, R.; Montaner, J.; and Wood, E. Crystal methamphetamine injection predicts slower HIV RNA suppression among injection drug users. Addict Beh 36(7):762–763, 2011.
  30. Chang, L.; Ernst, T.; Speck, O.; and Grob, C.S. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry 162:361–369, 2005.
  31. Rippeth, J.D.; Heaton, R.K.; Carey, C.L.; Marcotte, T.D.; Moore, D.J.; Gonzalez, R.; Wolfson, T.; and Grant, I. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10:1–14, 2004.
  32. Blackstone, K.; Iudicello, J.E.; Morgan, E.E. et al. Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-term methamphetamine use. Journal of Addiction Medicine 7(4):255–263, 2013.
  33. Rawson, R.A.; Marinelli-Casey, P.; Anglin, M.D.; Dickow, A.; Frazier, Y.; Gallagher, C.; Galloway, G.P.; Herrell, J.; Huber, A.; McCann, M.J.; Obert, J.; Pennell, S.; Reiber, C.; Vandersloot, D.; and Zweben, J. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 99:708–717, 2003.
  34. Huber, A.; Ling, W.; Shoptaw, S.; Gulati, V.; Brethen, P.; and Rawson, R. Integrating treatments for methamphetamine abuse: A psychosocial perspective. J Addict Dis 16(4):41–50, 1997.
  35. Petry, N.M.; Peirce, J.M.; Stitzer, M.L.; Blaine, J.; Roll, J.M.; Cohen, A.; Obert, J.; Killeen, T.; Saladin, M.E.; Cowell, M.; Kirby, K.C.; Sterling, R.; Royer- Malvestuto, C.; Hamilton, J.; Booth, R.E.; Macdonald, M.; Liebert, M.; Rader, L.; Burns, R.; DiMaria, J.; Copersino, M.; Stabile, P.Q.; Kolodner, K.; and Li, R. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: A National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry 62(10):1148–1156, 2005.
  36. U.S. Department of Justice DEA, Diversion Control Division. National Forensic Laboratory Information System (NFLIS) 2015 Annual Report. 2016.
  37. Chomchai C, Chomchai S. Global patterns of methamphetamine use. Curr Opin Psychiatry 2015;28:269-74.
  38. Panenka WJ, Procyshyn RM, Lecomte T, et al. Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend 2013;129:167-79.
  39. Moszczynska A. Neurobiology and clinical manifestations of methamphetamine neurotoxicity. Psychiatric Times 2016 Sept 30.
  40. Kish SJ. Pharmacologic mechanisms of crystal meth. Canadian Medical Association Journal 2008;178:1679.
  41. Artigiani EEH, M.H.; McCandlish, D.; and Wish, E.D. Methamphetamine: A Regional Drug Crisis. College Park, MD: National Drug Early Warning System 2018.
  42. CDC. CDC Wonder Multiple Cause of Death.
  43. Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend 2014;143:11-21.
  44. Administration USDoJDE. 2018 National Drug Threat Assessment 2018.
  45. Brown JD, Goodin AJ, Talbert JC. Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment. The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association 2017.
  46. Chiu VM, Schenk JO. Mechanism of action of methamphetamine within the catecholamine and serotonin areas of the central nervous system. Curr Drug Abuse Rev 2012;5:227-42.
  47. Rusyniak DE. Neurologic manifestations of chronic methamphetamine abuse. Psychiatr Clin North Am 2013;36:261-75.
  48. Akindipe T, Wilson D, Stein DJ. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. Metab Brain Dis 2014;29:351-7.
  49. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs 2014;28:1115-26.
  50. Ballester J, Valentine G, Sofuoglu M. Pharmacological treatments for methamphetamine addiction: current status and future directions. Expert Rev Clin Pharmacol 2017;10:305-14.
  51. Morley KC, Cornish JL, Faingold A, Wood K, Haber PS. Pharmacotherapeutic agents in the treatment of methamphetamine dependence. Expert Opinion on Investigational Drugs 2017;26:563-78.
  52. Makani R, Pradhan B, Shah U, Parikh T. Role of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment of Addiction and Related Disorders: A Systematic Review. Curr Drug Abuse Rev 2017;10:31-43.
  53. Rostami R, Dehghani-Arani F. Neurofeedback Training as a New Method in Treatment of Crystal Methamphetamine Dependent Patients: A Preliminary Study. Appl Psychophysiol Biofeedback 2015;40:151-61.
  54. Collins KC, Schlosburg JE, Bremer PT, Janda KD. Methamphetamine Vaccines: Improvement through Hapten Design. J Med Chem 2016;59:3878-85.
August 2011